01—Abstract
Summary
Summary of the 8-K filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported first quarter 2024 financial results and business updates on May 2, 2024, as furnished in Exhibit 99.1 to this Form 8-K.
Revenue for the quarter was $211.1 milliona, compared with $1.8 million in the prior-year period, primarily from recognition of non-refundable upfront payments under the Bayer and Kyowa Kirin exclusive license agreements. Operating costs and expenses rose to $210.8 million from $128.0 million, including $22.5 million of nonrecurring deal-related costs. The company reported a net loss of $36.2 million, or $0.20 per share, compared with a net loss of $142.7 million in the prior-year quarter.
Cash, cash equivalents, marketable securities and short-term restricted cash totaled $519.8 millionb at March 31, 2024, up from $392.6 million at December 31, 2023. The company highlighted acoramidis for ATTR-CM, with an NDA PDUFA date of November 29, 2024 set by the FDA and an MAA accepted by the EMA with approval expected in 2025. It also licensed European commercial rights to acoramidis to Bayer, in exchange for tiered royalties beginning in the low-thirties percent and up to $310 million in upfront and near-term milestone payments.
The company also launched BridgeBio Oncology Therapeutics (BBOT) with a $200 millionc private financing. Management stated that it believes it has a strong financial position to launch acoramidis in the U.S. at the end of 2024 and deliver three Phase 3 readouts in 2025. The balance sheet showed total stockholders' deficit of $1.05 billion at March 31, 2024, reflecting $737.4 million in 2029 Notes, $543.8 million in 2027 Notes and $434.7 million in term loan, net.
Net cash used in operating activities was $219.5 milliond for the quarter. The company also noted that Bristol-Myers Squibb (BMS) provided notice in March 2024 to terminate the Navire-BMS License Agreement, with termination effective in June 2024.
02—Key points
Key Highlights
- Revenue of $211.1 million vs. $1.8 million a year earlier, driven by non-refundable upfront payments under the Bayer and Kyowa Kirin exclusive license agreements
- Net loss of $36.2 million, or $0.20 per share, versus a net loss of $142.7 million in Q1 2023
- Cash, cash equivalents, marketable securities and short-term restricted cash of $519.8 million at March 31, 2024, up from $392.6 million at December 31, 2023
- Acoramidis for ATTR-CM has a November 29, 2024 PDUFA date from the FDA, and the EMA accepted its MAA with approval expected in 2025
- Bayer licensed European commercial rights to acoramidis, with tiered royalties beginning in the low-thirties percent and up to $310 million in upfront and near-term milestone payments
- Launch of BridgeBio Oncology Therapeutics (BBOT) with a $200 million private financing led by Cormorant Asset Management and co-led by Omega Funds
- BMS gave notice in March 2024 to terminate the Navire-BMS License Agreement, with termination effective in June 2024
03—Questions
Frequently Asked Questions
What drove the increase in revenue this quarter?
Revenue was $211.1 million versus $1.8 million in the prior-year quarter, primarily due to recognition of non-refundable upfront payments under the Bayer and Kyowa Kirin exclusive license agreements.
How did operating expenses change?
Operating costs and expenses were $210.8 million, up from $128.0 million, with research and development and other expenses increasing $48.1 million and SG&A increasing $34.7 million. Operating costs include $22.5 million of nonrecurring deal-related costs.
What are the key regulatory milestones for acoramidis?
The FDA set a PDUFA date of November 29, 2024 for the NDA for acoramidis in ATTR-CM. The EMA accepted the MAA for review, with approval expected in 2025.
How did the company strengthen its financial position?
The company secured up to $1.5 billion in a Q1 2024 capital campaign, including a term loan under the Blue Owl credit facility with net proceeds of $437.7 million, net equity financing proceeds of $315.3 million, and the Bayer licensing agreement. Cash, cash equivalents and marketable securities ended the quarter at $519.8 million.
What happened with the Bristol-Myers Squibb agreement?
BMS provided notice in March 2024 to terminate the Navire-BMS License Agreement, with termination effective in June 2024. Revenue recognized from this agreement during the quarter was part of the remaining license and services revenue.
04—Continue